基本信息
浏览量:496
职业迁徙
个人简介
He has been involved in the development of immunotherapy in bladder cancer since its inception. He has participated on the two phase I trials with atezolizumab (Nature. 2014) and with pembrolizumab (Lancet Oncol. 2017) and the phase II atezolizumab (Lancet 2016) that led to the FDA approval of both agents. Along the same line, he has contributed to the development of these agents in unfit bladder cancer patients (Lancet 2017). One of the most important contributions in bladder cancer have been to be the lead investigator of the phase III randomized study of vinflunine versus BSC and of the pembrolizumab versus chemotherapy that both led to the approval for these agents in the second line. The last trial is a landmark trial showing survival superiority for immunotherapy versus chemotherapy. The results of this last study were published in the NEJM (Bellmunt J, N Engl J Med. 2017). He has also been the PI of the IMvigor 010 study (adjuvant atezolizumab in bladder cancer) that led to the identification of ctDNA utility for MRD monitoring in bladder cancer. He is the co-author of the Javelin 100 study that has led to the recent approval of maintenance avelumab. He is a member of SEOM, SOGUG, ASCO and ESMO.
研究兴趣
论文共 963 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
EUROPEAN UROLOGYno. 2 (2024): 154-163
Srikala S. Sridhar,Thomas Powles, Shilpa Gupta, Climent Miguel A. Duran,Jeanny B. Aragon-Ching,Cora N. Sternberg,Howard Gurney, Paul Cislo, Nuno Costa,Alessandra di Pietro,Joaquim Bellmunt,Petros Grivas
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2023): 58-59
引用0浏览0引用
0
0
Journal of Clinical Oncologyno. 3 (2023): 629-639
引用16浏览0引用
16
0
JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023): 4516-4516
引用0浏览0引用
0
0
openalex(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn